WallStSmart

IQVIA Holdings Inc (IQV)vsOpko Health Inc (OPK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 2588% more annual revenue ($16.31B vs $606.88M). IQV leads profitability with a 8.3% profit margin vs -37.2%. IQV appears more attractively valued with a PEG of 0.97. IQV earns a higher WallStSmart Score of 72/100 (B).

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33

OPK

Avoid

31

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 4.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued

Intrinsic value data unavailable for OPK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

OPK1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Areas to Watch

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

OPK4 concerns · Avg: 2.3/10
Market CapQuality
$859.83M3/10

Smaller company, higher risk/reward

PEG RatioValuation
93.652/10

Expensive relative to growth rate

Return on EquityProfitability
-17.1%2/10

ROE of -17.1% — below average capital efficiency

Revenue GrowthGrowth
-19.2%2/10

Revenue declined 19.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : OPK

The strongest argument for OPK centers on Price/Book.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Bear Case : OPK

The primary concerns for OPK are Market Cap, PEG Ratio, Return on Equity.

Key Dynamics to Monitor

IQV profiles as a value stock while OPK is a turnaround play — different risk/reward profiles.

OPK carries more volatility with a beta of 1.52 — expect wider price swings.

IQV is growing revenue faster at 10.3% — sustainability is the question.

IQV generates stronger free cash flow (561M), providing more financial flexibility.

Bottom Line

IQV scores higher overall (72/100 vs 31/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Opko Health Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.

Want to dig deeper into these stocks?